Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Evoke Pharma, Inc. (EVOK : NSDQ)
 
 • Company Description   
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.

Number of Employees: 3

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.72 Daily Weekly Monthly
20 Day Moving Average: 15,877 shares
Shares Outstanding: 1.49 (millions)
Market Capitalization: $4.06 (millions)
Beta: -0.04
52 Week High: $8.00
52 Week Low: $1.94
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.80% -11.89%
12 Week 23.64% 5.60%
Year To Date -38.46% -42.36%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
420 STEVENS AVENUE SUITE 370
-
SOLANA BEACH,CA 92075
USA		 ph: 858-345-1494
fax: -		 dboateng@dkbpartners.net http://www.evokepharma.com
 
 • General Corporate Information   
Officers
Matthew J. D'Onofrio - Chief Executive Officer
Cam L. Garner - Chairman
Mark Kowieski - Chief Financial Officer
Todd C. Brady - Director
Vickie W. Reed - Director

Peer Information
Evoke Pharma, Inc. (BGMR)
Evoke Pharma, Inc. (BBIO)
Evoke Pharma, Inc. (IPAH)
Evoke Pharma, Inc. (BRL)
Evoke Pharma, Inc. (BHC)
Evoke Pharma, Inc. (AKRXQ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-GENERIC DRG
Sector: Medical
CUSIP: 30049G302
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 1.49
Most Recent Split Date: 8.00 (0.08:1)
Beta: -0.04
Market Capitalization: $4.06 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.70
Price/Cash Flow: -
Price / Sales: 0.35
EPS Growth
vs. Year Ago Period: 75.01%
vs. Previous Quarter: -4.08%
Sales Growth
vs. Year Ago Period: 77.42%
vs. Previous Quarter: -6.89%
ROE
06/30/25 - -
03/31/25 - -101.91
12/31/24 - -121.73
ROA
06/30/25 - -
03/31/25 - -33.75
12/31/24 - -38.05
Current Ratio
06/30/25 - -
03/31/25 - 1.55
12/31/24 - 1.66
Quick Ratio
06/30/25 - -
03/31/25 - 1.50
12/31/24 - 1.62
Operating Margin
06/30/25 - -
03/31/25 - -43.80
12/31/24 - -52.22
Net Margin
06/30/25 - -
03/31/25 - -43.80
12/31/24 - -52.22
Pre-Tax Margin
06/30/25 - -
03/31/25 - -43.80
12/31/24 - -52.22
Book Value
06/30/25 - -
03/31/25 - 3.91
12/31/24 - 4.74
Inventory Turnover
06/30/25 - -
03/31/25 - 0.61
12/31/24 - 0.69
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©